Sebastian Bauer

25.8k citations

367 papers · 10.2k indexed · 3 hit papers · h-index 47

Impact in

Gastroenterology top 0.1%
- Gastrointestinal Tumor Research and Treatment
Pulmonary and Respiratory Medicine top 0.2%
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes

Papers in

Gastroenterology 124
- Gastrointestinal Tumor Research and Treatment 124
Pulmonary and Respiratory Medicine 221
- Sarcoma Diagnosis and Treatment 143
- Gastric Cancer Management and Outcomes 64

Co-authors: Patrik Schmuki Hiroaki Tsuchiya Jan M. Macák Andrei Ghicov Robert Hahn Kouji Yasuda George D. Demetri Jonathan A. Fletcher
Journals: Journal of Clinical Oncology (62 papers)Annals of Oncology (33 papers)European Journal of Cancer (16 papers)Cancer Research (10 papers)Clinical Cancer Research (8 papers)
Partner nations: Germany United States France

In The Last Decade

Sebastian Bauer

350 papers receiving 10.0k citations

Hit Papers

align trajectories log scale

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial 2020 · 251 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 The Lancet Oncology
2016 The Lancet
2007 Current Opinion in Solid State and Materials Science

Peers

Countries citing papers authored by Sebastian Bauer

Since Specialization

Citations

This map shows the geographic impact of Sebastian Bauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sebastian Bauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sebastian Bauer more than expected).

Fields of papers citing papers by Sebastian Bauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sebastian Bauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sebastian Bauer. The network helps show where Sebastian Bauer may publish in the future.

Co-authors

The 25 scholars most cited alongside Sebastian Bauer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sebastian Bauer Line = papers co-authored together Sebastian Bauer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial) Clinical Cancer Research ·Johanna Falkenhorst, Philipp Ivanyi, Tom Schulz, Rainer Hamacher, Bernd Kasper, Peter Hohenberger, Christoph K.W. Deinzer, Daniel Pink, Benjamin S. Fletcher, Valerie Haller, Yasmin Optaczy, Susanne Grünewald, Daniel Rauh, Adrián Mariño‐Enríquez, Thomas Mühlenberg, Peter Reichardt, Sebastian Bauer	2025	0
2	Electronic Nose for Indoor Mold Detection and Identification Advanced Sensor Research ·Hankun Yang, Martin Sommer, Sebastian Bauer, Uli Lemmer	2025	0
3	Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study The Oncologist ·Andrew J. Wagner, William D. Tap, Sebastian Bauer, Jean‐Yves Blay, Jayesh Desai, Hans Gelderblom, Emanuela Palmerini, Christopher W. Ryan, Charles Peterfy, John H. Healey, Michiel A. J. van de Sande, Meng Qian, Dale E. Shuster, Abdul Waheed Rajper, Xin Ye, Kristen M. Tecson, Margaret Wooddell, Silvia Stacchiotti	2025	1
4	Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial. Journal of Clinical Oncology ·William D. Tap, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean‐Yves Blay, Hans Gelderblom, (unknown)	2024	2
5	From Static to Dynamic Structures: Improving Binding Affinity Prediction with Graph‐Based Deep Learning Advanced Science ·Yaosen Min, Wei Ye, Peizhuo Wang, Xiaoting Wang, Han Li, Nian Wu, Sebastian Bauer, Shuxin Zheng, Yu Shi, Yingheng Wang, Ji Wu, Dan Zhao, Jianyang Zeng	2024	13
6	Machine learning in microscopy – insights, opportunities and challenges Journal of Cell Science ·Inês Cunha, Emma Latron, Sebastian Bauer, Daniel Sage, Juliette Griffié	2024	7
7	Evaluation of the Effect of Photodynamic Therapy on CAM-Grown Sarcomas Bioengineering ·Maximilian Kerkhoff, Susanne Grünewald, Christiane Schaefer, Stefan Zöllner, Pauline Plaumann, Maike Busch, Nicole Dünker, Julia Ketzer, Josephine Kersting, Sebastian Bauer, Jendrik Hardes, Arne Streitbürger, Uta Dirksen, Wolfgang Hartmann, Wiebke K. Guder	2023	4
8	Clinical Benefit of Avapritinib in KIT- Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies Clinical Cancer Research ·Michael C. Heinrich, Xinhua Zhang, Robin L. Jones, Suzanne George, César Serrano, Yanhong Deng, Sebastian Bauer, Shirong Cai, Xin Wu, Yongjian Zhou, Kaixiong Tao, Zhichao Zheng, Jun Zhang, Yuehong Cui, Hui Cao, Meining Wang, Jin Hu, Jason Yang, Jian Li, Lin Shen	2023	4
9	Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial Journal of Clinical Oncology ·Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich	2022	61
10	Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities Clinical Cancer Research ·Wolfgang P. Fendler, Kim M. Pabst, Lukas Kessler, Pedro Fragoso Costa, Justin Ferdinandus, Manuel Weber, Maria Lippert, Katharina Lueckerath, Lale Umutlu, Karina Kostbade, Ilektra A. Mavroeidi, Martin Schüler, Marit Ahrens, Christoph Rischpler, Sebastian Bauer, Ken Herrmann, Jens T. Siveke, Rainer Hamacher	2022	91
11	Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion Radiology and Oncology ·Johannes Ludwig, Johannes Haubold, Sebastian Bauer, Heike Richly, Jens T. Siveke, Julia Wimmer, Lale Umutlu, Benedikt M. Schaarschmidt, Jens Theysohn	2021	9
12	Surgical Treatment for Primary Chest Wall Sarcoma: A Single-Institution Study Journal of Surgical Research ·Stéphane Collaud, Theresa Störk, Uta Dirksen, Christoph Pöttgen, Balázs Hegedűs, Hans‐Ulrich Schildhaus, Sebastian Bauer, Clemens Aigner	2020	7
13	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial European Journal of Cancer ·Patrick Schöffski, Agnieszka Woźniak, Bernard Escudier, Piotr Rutkowski, Alan Anthoney, Sebastian Bauer, Jozef Šufliarský, Carla van Herpen, Lars H. Lindner, Viktor Grünwald, Branko Zakotnik, Evelyne Lerut, Maria Dêbiec‐Rychter, Sandrine Marréaud, Michela Lia, Tiana Raveloarivahy, Sandra Collette, Laurence Albigès	2017	94
14	Sustained Mutant KIT Activation in the Golgi Complex Is Mediated by PKC-θ in Gastrointestinal Stromal Tumors Clinical Cancer Research ·Won Kyu Kim, SeongJu Yun, Cheol Keun Park, Sebastian Bauer, Jiyoon Kim, Min Goo Lee, Hoguen Kim	2016	10
15	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial Journal of Clinical Oncology ·Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Jörg T. Hartmann, Daniel Pink, Giuliano Ramadori, Peter Hohenberger, Salah‐Eddin Al‐Batran, M. Schlemmer, Sebastian Bauer, Eva Wardelmann, Bengt Nilsson, Harri Sihto, Petri Bono, Raija Kallio, Jouni Junnila, Thor Alvegård, Peter Reichardt	2015	149
16	Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients Clinical Cancer Research ·Andrew P. Garner, Joseph M. Gozgit, Rana Anjum, Sadanand Vodala, Alexa B. Schrock, Tianjun Zhou, César Serrano, Grant Eilers, Mei‐Jun Zhu, Julia Ketzer, Scott Wardwell, Yaoyu Ning, Youngchul Song, Anna Kohlmann, Frank Wang, Tim Clackson, Michael C. Heinrich, Jonathan A. Fletcher, Sebastian Bauer, Victor M. Rivera	2014	123
17	DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal Tumors Cancer Research ·Susanne Simon, Florian Grabellus, Loretta Ferrera, Luis J. V. Galietta, Benjamin Schwindenhammer, Thomas Mühlenberg, G. Taeger, Grant Eilers, Juergen Treckmann, Frank Breitenbuecher, Martin Schüler, Takahiro Taguchi, Jonathan A. Fletcher, Sebastian Bauer	2013	67
18	Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST) European Journal of Cancer ·Sebastian Bauer, Jean‐Yves Blay, Paolo G. Casali, Peter Reichardt, Yiming Kang, Piotr Rutkowski, Hans Gelderblom, Peter Hohenberger, Christian Kappeler, I. Kuss, George D. Demetri	2013	1
19	Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors Cancer Research ·Thomas Mühlenberg, Yixiang Zhang, Andrew J. Wagner, Florian Grabellus, James E. Bradner, G. Taeger, Hauke Lang, Takahiro Taguchi, Martin Schüler, Jonathan A. Fletcher, Sebastian Bauer	2009	74
20	Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells Cancer Research ·Sebastian Bauer, Joshua A. Parry, Thomas Mühlenberg, Matthew F. Brown, Danushka S. Seneviratne, Payel Chatterjee, Anna Chin, Brian P. Rubin, Shih-Fan Kuan, Jonathan A. Fletcher, Stefan Duensing, Anette Duensing	2009	34

About Sebastian Bauer

Sebastian Bauer is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine, Oncology, Hematology and Rheumatology, having authored 367 papers that have together received 10.2k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (143 papers), Gastrointestinal Tumor Research and Treatment (124 papers), Gastric Cancer Management and Outcomes (64 papers), Vascular Tumors and Angiosarcomas (41 papers), Gastrointestinal disorders and treatments (28 papers), Cardiac tumors and thrombi (26 papers), Neurofibromatosis and Schwannoma Cases (25 papers) and Cancer Genomics and Diagnostics (18 papers). The work is most often cited by research in Gastroenterology (2.5k citations), Pulmonary and Respiratory Medicine (4.3k citations), Oncology (2.4k citations), Renewable Energy, Sustainability and the Environment (1.2k citations) and Neurology (896 citations). Sebastian Bauer has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Patrik Schmuki, Hiroaki Tsuchiya, Jan M. Macák, Andrei Ghicov, Robert Hahn, Kouji Yasuda, George D. Demetri, Jonathan A. Fletcher, Norbert Stock and Patrick Schöffski. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact